This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-17 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Michel Janicot
Chief Development Officer at InteRNA Technologies

Profile

Michel holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from University Paris VII (France) and was Postdoctoral Fellow at The Johns Hopkins University (Baltimore, MD. USA). He has over 35 years of professional experience in Oncology preclinical and early clinical pharmaceutical drug development in increasing leadership roles at Rhone-Poulenc Rorer (Sanofi) and Janssen (Johnson & Johnson). Since 2012, Michel is the founder and General Manager of JMi ONConsulting, a consulting firm specialized in providing services and guidances for R&D programs (small molecules and biologicals) in the field of Oncology, Inflammation, Immunology, Fibrosis and Ophthalmology, with strong strategic focus on RNA therapeutics. He is also co-founder and Board member of aPODD, a non-profit foundation focusing on Pediatric Oncology.

Agenda Sessions

  • INT-1B3 (miR-193a-3p mimic) Preclinical Development: Translational Medicine Perspectives for Advanced Cancer Patients

    16:50